Phase II trial of bevacizumab + cetuximab + cisplatin with concurrent intensity-modulated radiation therapy for patients with stage III/IVB head and neck squamous cell carcinoma
详细信息 查看全文
- 作者：Matthew G. Fury ; Han Xiao ; Eric J. Sherman ; Shrujal Baxi ; Stephanie Smith-Marrone ; Karen Schupak ; Richard Gewanter ; Daphna Gelblum ; Sofia Haque ; Heiko Schoder ; Jatin P. Shah ; Nora Katabi ; Rachel Kurtzman ; Brynna Lipson ; Lisa Cox ; Nancy Y. Lee and David G. Pfister
- 关键词：squamous ; neck ; bevacizumab ; human papillomavirus ; intensity-modulated radiation therapy (IMRT)
- 刊名：Head & Neck
- 出版年：2016
- 出版时间：April 2016
- 年：2016
- 卷：38
- 期：S1
- 页码：E566-E570
- 全文大小：198K
- ISSN：1097-0347
文摘
The purpose of this study was to evaluate the efficacy and tolerability of the addition of 2 monoclonal antibodies, bevacizumab and cetuximab, to 2 cycles of high-dose cisplatin administered concurrently with intensity-modulated radiation therapy (IMRT) for head and neck squamous cell carcinoma (HNSCC).